Migraine biotech Vedana Therapeutics makes its debut with $46M Series A

From L-R: executive chair Rob Lenz, CSO Leon Garcia, CEO Anurag Agarwal and CMO Ernesto Aycardi (courtesy Vedana Therapeutics) June 17, 2026 05:00 AM EDT FinancingStartups Mi­graine biotech makes its de­but with $46M to ad­vance pre­clin­i­cal pipeline Ayisha Sharma News Reporter Vedana Ther­a­peu­tics has emerged from stealth with $46 mil­lion in Se­ries A pro­ceeds with the goal of de­vel­op­ing treat­ments that could free pa­tients from mi­graines … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER